Elevated adrenomedullin has been considered as an independent predictor of AIS outcomes in recent years (56) and a novel plasma biomarker related to the increased mortality in AIS patients undergoing early rehabilitation (57), possibly due to the involvement of adrenomedullin receptor genes in vascular injury (58). The gene discussed is ADM; the disease is androgen insensitivity syndrome.